Magazine Article | August 23, 2017

Part D Is Due For A Tune-Up

Source: Life Science Leader

By John McManus, president and founder, The McManus Group

Lost in the hubbub over drug pricing has been the flat and declining spending recently in Part D. The Congressional Budget Office’s (CBO) June 2017 Baseline projections show that Part D spending stabilized at $95 billion annually for 2016 and 2017 and will decline to $92 billion in 2018